Has Merck Lucked Into A $10 Billion Drug?

Merck–and its cancer drug Keytruda–had a great day yesterday.

First, rival drug giant Roche revealed that a clinical trial failed to show its Tecentriq, a drug similar to Keytruda, extended the lives of patients with bladder cancer. Keytruda, by contrast, had added a median 3.1 months to patients’ lives in a similar study. Then, late last night, Keytruda was approved as a first choice for most patients with non-small cell lung cancer when used in combination with a chemotherapy regimen that includes Eli Lilly’s Alimta.

Read Full Article Here >>